Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AstraZeneca Board Rejects Pfizer Proposal

Published: Friday, May 02, 2014
Last Updated: Friday, May 02, 2014
Bookmark and Share
The financial and other terms of the proposal have been described as inadequate, substantially undervaluing AstraZeneca.

The large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged. Accordingly, the Board has rejected the Proposal.

Leif Johansson, Chairman of AstraZeneca, said: “AstraZeneca continues to invest significantly in research, development and manufacturing in the U.K., Sweden and the U.S. We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the Board believes will deliver significant value for shareholders. Pfizer’s proposal would dramatically dilute AstraZeneca shareholders’ exposure to our unique pipeline and would create risks around its delivery. As such, the Board has no hesitation in rejecting the Proposal.”

AstraZeneca have advised shareholders to take no action. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Monday, April 25, 2016
AstraZeneca, Univ. of Manchester Partner
AstraZeneca and The University of Manchester have announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients.
Wednesday, September 09, 2015
Heptares, AstraZeneca Collaborate
The companies are set to enter into an agreement to develop novel immuno-oncology treatments for a range of cancers.
Monday, August 10, 2015
AstraZeneca, Lilly to Study Immuno-Oncology Combination
This collaboration sets out to assess the efficacy of a combinatorial treatment in patients with advanced solid state tumors.
Monday, June 01, 2015
AstraZeneca and Harvard Stem Cell Institute Collaborate
Collaboration will develop the use of stem cells for diabetes research.
Wednesday, March 25, 2015
AstraZeneca Reveals Designs for Cambridge Headquarters
Company revealed the proposed designs for its new Global R&D Centre and Corporate Headquarters in Cambridge in the UK.
Friday, July 18, 2014
AstraZeneca and the Broad Institute Collaborate
Partnership to advance discovery of antibacterial and antiviral agents.
Tuesday, September 11, 2012
AstraZeneca to Provide UK Academics with Access to Compound Library
Their groundbreaking new collaboration with the Medical Research Council (MRC) will see the company providing the UK academic sector with access to 22 drugs.
Friday, December 09, 2011
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!